> > >

Meet Our Representatives

Meet Steve, Jesús, and Tom, 3 Novo Nordisk Representatives who work directly with the hemophilia community. Hear about how Novo Nordisk has committed to addressing the community’s unique needs and how much they enjoy their role in helping to improve the lives of people living with hemophilia.

Play
Pause
Skip
Volume
Chapters
Transcript
References
Subtitles
Fullscreen

Meet Our Representatives

Chapters
Transcript
References

Meet Steve, Jesús, and Tom, 3 Novo Nordisk Representatives who work directly with the hemophilia community. Hear about how Novo Nordisk has committed to addressing the community’s unique needs and how much they enjoy their role in helping to improve the lives of people living with hemophilia.

Return to overview

Chapters

Return to overview

Transcripts

Return to overview

References


Related Videos

Team Novo8™


Team Novo8™ is a group of patients who switched to Novoeight® and spend their time helping others with hemophilia A. Hear more about their mission, and how your patients may benefit from their experiences.
 

Meet Team Novo8™

Available from Novo Nordisk:

NovoSeven® RT Logo

Visit website  | Prescribing Information

Rebinyn® Logo

Visit website  | Prescribing Information

Visit website | Prescribing Information

Selected Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Prescribing Information.